ESMO Congress 2020 - European Society of Medical Oncology Listing

Lorlatinib ‘highly effective option’ for certain NSCLC patients

A head-to head trial shows it might be particularly effective in preventing intracranial progression, researchers say.

Neither mono nor dual immune checkpoint inhibitor therapy improved survival in multi-nation study.

But two trials of first-line therapy have differing overall survival outcomes.

The hunt is on for ways to predict response to immune checkpoint inhibitors in NSCLC.

Osimertinib is a practice-changing treatment for certain patients with completely resected EGFR-mutated disease, researcher says.

Interim results from the open-label trial suggest abemaciclib has benefit, researchers say.

Trial findings clarify lack of benefit and increased cardiopulmonary toxicity.

Trial results show improved clinical outcome in a subset of men with castration-resistant disease, researchers say.

Results from a phase 2 trial with letrozole in oestrogen receptor-positive patients.

The first results of the CheckMate 9ER trial show a good response rate and improved survival, researchers say.